Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117946 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL1063199 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29349956 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31714182 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29358863 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL119588 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31369598 | 0.97 | MDM2 (0.53) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516252 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516240 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516235 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775353-A | Short peptide compound and preparation method thereof, cosmetic composition and application | 常州市智态生创科技有限公司 | 2025-04-08 | — | — | CN | claimed |
| CN-116751139-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-tyrosine | 山西诺成制药有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-112159461-B | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-112279890-B | Amphiphilic polypeptide, preparation method and application | 皖南医学院 | 2022-10-11 | — | — | CN | claimed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| CN-119775353-A | Short peptide compound and preparation method thereof, cosmetic composition and application | 常州市智态生创科技有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115053184-B | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2024-12-06 | — | — | CN | disclosed |
| CN-115073587-B | Synthesis process for synthesizing bivalirudin by semi-continuous liquid phase synthesis | 厦门胜泽泰医药科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| EP-4337674-A2 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2024-03-20 | — | — | EP | disclosed |
| CN-116751139-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-tyrosine | 山西诺成制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751139-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-tyrosine | 山西诺成制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116751139-A | Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-tyrosine | 山西诺成制药有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-110475785-B | Peptide compound, method for producing same, composition for screening, and method for selecting peptide compound | 富士胶片株式会社 | 2023-06-13 | — | — | CN | disclosed |
| CN-112159461-B | Synthesis method of cetrorelix | 开封明仁药业有限公司 | 2023-03-10 | — | — | CN | disclosed |
| WO-2022238565-A2 | COMPOUNDS | INSUSENSE ApS (DK) | 2022-11-17 | — | — | WO | disclosed |
| CN-112279890-B | Amphiphilic polypeptide, preparation method and application | 皖南医学院 | 2022-10-11 | — | — | CN | disclosed |
| CN-115053184-A | Composition for forming EUV resist underlayer film | 日产化学株式会社 | 2022-09-13 | — | — | CN | disclosed |
| CN-112094204-B | Method for preparing Fmoc-Tyr (tBu) -OH | 成都郑源生化科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-114106091-A | Protein analogs and conjugates thereof | 正大天晴药业集团股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-113845569-B | Synthetic method of pasireotide intermediate | 浙江湃肽生物有限公司南京分公司 | 2022-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | MDM4 2510/4885TP53 112/4885MDM2 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.